iTeos Therapeutics (NASDAQ:ITOS) Posts Earnings Results, Beats Expectations By $0.13 EPS

iTeos Therapeutics (NASDAQ:ITOS) issued its quarterly earnings data on Wednesday. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.13, Zacks reports.

iTeos Therapeutics Stock Performance

Shares of ITOS traded up $0.31 during trading hours on Wednesday, hitting $7.16. 20,618 shares of the company were exchanged, compared to its average volume of 446,114. The company has a market cap of $261.58 million, a PE ratio of -2.27 and a beta of 1.38. The firm’s 50 day moving average is $7.54 and its 200-day moving average is $9.57. iTeos Therapeutics has a 52 week low of $6.67 and a 52 week high of $18.75.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, January 16th. Wells Fargo & Company decreased their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Finally, Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research note on Friday, January 10th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.